Objective-Plaque erosion is increasing its importance as one of the mechanisms of acute coronary syndromes in this statin era. However, the clinical efficacy of currently used lipid-lowering agents in the prevention of thrombotic complications associated with plaque erosion has not been clarified. Therefore, we examined the therapeutic effects of ezetimibe or rosuvastatin monotherapy on spontaneous atherothrombotic occlusion. Approach and Results-Femoral arteries of Japanese white rabbits, fed a high-cholesterol diet, were injured by balloon catheter, and then angiotensin II was continuously administrated. In 94% of these arteries, spontaneous thrombotic occlusions were observed after 5 weeks (median) of balloon injury. Histochemical analyses indicated that the injured arteries had similar pathological features to human plaque erosions; (1) spontaneous thrombotic occlusion, (2) lack of endothelial cells, and (3) tissue factor expression in vascular smooth muscle cells. Ezetimibe (1.0 mg/kg per day), but not rosuvastatin (0.6 mg/kg per day), significantly decreased thrombotic occlusion of arteries accompanied with accelerated re-endothelialization and the decreases of serum oxysterols despite the comparable on-treatment serum cholesterol levels. The 7-ketocholesterol inhibited the migration of human umbilical vein endothelial cells. Both 7-ketocholesterol and 27-hydroxycholesterol increased tissue factor expression in cultured rat vascular smooth muscle cells. Tissue factor expression was also induced by serum from vehicle-or rosuvastatin-treated rabbits, but the induction was attenuated with serum from ezetimibe-treated rabbits. events remain even after intensive lipid-lowering treatment with statins. 16 In addition, it is unknown whether lipid-lowering therapies prevent thrombus formation after plaque erosion because of the lack of an appropriate animal model and evaluation method of plaque erosion. Clinical trials indicate that residual risks remain even after the administration of statins, 17 and these risks are associated with the observation that the lowering of low-density lipoprotein cholesterol levels by statins is counteracted by enhanced absorption of cholesterol and other atherogenic lipids, including oxysterols, from the small intestine. 18, 19 Oxysterols found in mammals in vivo are enzymatically generated during cholesterol catabolism (eg, is formed enzymatically through sterol 27-hydroxylase especially expressing in the liver) or nonenzymatically generated depending on oxidative stress in vivo or oxidation during cooking (eg,; Figure I in the online-only Data Supplement). 20 Ezetimibe lowers serum cholesterol, including dietary oxysterols, by blocking the cholesterol transporter Niemann-pick C1-like 1 in the small intestine. 21, 22 The addition of ezetimibe to statin treatment in patients after ACS further decreased the rate of cardiovascular events compared with statin monotherapy. 23 Furthermore, the QcVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting) has shown that compared with statin monotherapy, the combination of ezetimibe and statins improves functional prognoses and ameliorates endothelial dysfunction in stented coronary arteries, which is associated with a reduction in oxysterol levels. 24 These findings led us to hypothesize that ezetimibe prevents atherothrombotic occlusion after plaque erosion via different mechanisms from statins.
P laque rupture and plaque erosion are the 2 major causes of thrombotic occlusion in coronary arteries that lead to acute coronary syndrome (ACS). 1, 2 Atherosclerotic plaques prone to rupture have common pathological features, for example, a thin fibrous cap, macrophage infiltration, and a large necrotic core, 3, 4 which led to the concept of vulnerable plaques. 4 Most previous studies on ACS have focused on these vulnerable plaques. [5] [6] [7] Imaging modalities, such as intravascular ultrasound and optical coherence tomography, have been used to observe plaque ruptures in ACS culprit lesions. 4, [8] [9] [10] However, plaque erosion, found in 35% to 40% individuals with sudden coronary death, is associated with thrombotic events without fibrous cap rupture. 1 Typical eroded plaques in humans are pathologically characterized by the absence of an endothelial layer, poor infiltration of inflammatory cells, and abundant smooth muscle cells (SMCs).
11,12 TF (tissue factor) expression in intimal SMCs has been reported in a previous animal model of plaque erosion. 13 However, the detailed mechanisms of plaque erosion and subsequent thrombus formation are not fully understood.
Advances in cardiovascular science, including percutaneous coronary intervention, have highlighted the importance of medical treatment for secondary prevention. Statins are widely used as standard agents for lipid-lowering therapy and have succeeded in decreasing recurrent coronary events prone to plaque ruptures by stabilizing atherosclerotic plaques underpinned by thick fibrous caps, less lipid accumulation, and less inflammation, 6, 14, 15 but residual risks of cardiovascular events remain even after intensive lipid-lowering treatment with statins. 16 In addition, it is unknown whether lipid-lowering therapies prevent thrombus formation after plaque erosion because of the lack of an appropriate animal model and evaluation method of plaque erosion. Clinical trials indicate that residual risks remain even after the administration of statins, 17 and these risks are associated with the observation that the lowering of low-density lipoprotein cholesterol levels by statins is counteracted by enhanced absorption of cholesterol and other atherogenic lipids, including oxysterols, from the small intestine. 18, 19 Oxysterols found in mammals in vivo are enzymatically generated during cholesterol catabolism (eg, 27-hydroxycholesterol [27HC] is formed enzymatically through sterol 27-hydroxylase especially expressing in the liver) or nonenzymatically generated depending on oxidative stress in vivo or oxidation during cooking (eg, 7-ketocholesterol [7KC]; Figure I in the online-only Data Supplement). 20 Ezetimibe lowers serum cholesterol, including dietary oxysterols, by blocking the cholesterol transporter Niemann-pick C1-like 1 in the small intestine. 21, 22 The addition of ezetimibe to statin treatment in patients after ACS further decreased the rate of cardiovascular events compared with statin monotherapy. 23 Furthermore, the QcVIC trial (Effect of Cholesterol Absorption Inhibitor Usage on Target Vessel Dysfunction After Coronary Stenting) has shown that compared with statin monotherapy, the combination of ezetimibe and statins improves functional prognoses and ameliorates endothelial dysfunction in stented coronary arteries, which is associated with a reduction in oxysterol levels. 24 These findings led us to hypothesize that ezetimibe prevents atherothrombotic occlusion after plaque erosion via different mechanisms from statins.
Therefore, the objective of this study was to examine the efficacy of ezetimibe treatment in preventing thrombotic occlusion after plaque erosion. To this end, we first developed an animal model of spontaneous thrombotic occlusion after endothelial denudation without plaque rupture and examined the efficacy of ezetimibe monotherapy versus statin monotherapy in this model to clarify the vasculoprotective property of ezetimibe in comparison to statin. This study is meaningful because it is not practical to perform clinical studies to elucidate the role of ezetimibe in the prevention of atherosclerosis and thrombosis by comparing ezetimibe monotherapy with the combination of ezetimibe and statins. [23] [24] [25] To develop the rabbit model of plaque erosion, we added chronic infusion of angiotensin II to a widely adopted rabbit neointimal formation model. 26, 27 Angiotensin II was used because it (1) promotes inflammation, [28] [29] [30] (2) induces prothrombotic mediators, such as TF in monocytes, endothelial cells (ECs), and vascular SMCs (VSMCs), which increase the risk of atherosclerotic cardiovascular diseases, [31] [32] [33] and (3) inhibits re-endothelialization of injured arteries by inducing endothelial apoptosis.
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Materials and Methods
Experimental Animals
Japanese white rabbits were purchased from KBT Oriental (Tokyo, Japan). All rabbits were maintained on a 12-hour light/dark cycle and given water and normal chow. All study protocols were reviewed and approved by the Committee on the Ethics of Animal Experiments, Kyushu University Graduate School of Medical Sciences, and were performed according to the guidelines of the National Institutes of Health Guide for the Care and Use of Laboratory Animals.
Experimental Protocol 1
Male Japanese white rabbits weighing 2.5 to 3.0 kg were fed a highcholesterol diet containing 1% cholesterol and 3% peanut oil for 2 weeks (days 0-14). On day 14, the animals were anesthetized by an intramuscular injection of xylazine (3 mg/kg) and ketamine (35 mg/ kg), and the bilateral femoral arteries were injured by 3 passages of an inflated percutaneous transluminal coronary angioplasty balloon catheter (3.0×20 mm, Microport Scientific, Shanghai, China) to 2 atm. To avoid balloon injury-related acute thrombosis, aspirin (20 mg/d) was administered orally for 1 week before and after balloon injury (days 7-21). Immediately after balloon injury, the rabbits were randomly divided into 2 groups: (1) the angiotensin II (−) vehicle group (n=5) received PBS (50 ng/kg per minute) via osmotic mini-pump (Alzet model 2006, Cupertino, CA) for 8 weeks (days 14-70) and (2) the angiotensin II-treated group (n=6) received an angiotensin II (catalog number A9525, Sigma, 50 ng/kg per minute) infusion dissolved in PBS via osmotic mini-pump for the same length of time. On day 42, blood samples were collected, and the osmotic mini-pumps were replaced for further angiotensin II infusion. Highresolution ultrasound echography was performed 3× a week during the experimental period with a Vevo 2100 system (VisualSonics, Toronto, Canada) equipped with 40 MHz linear array transducers. B-mode, color Doppler, and pulse Doppler studies were performed to confirm the patency of the balloon-injured arteries. When the absence of blood flow was suspected by ultrasound echography, isosorbide dinitrate (0.3 mg) was injected intravenously to rule out arterial vasospasm. When blood flow was not detected by ultrasound echography again, we performed an angiography of the femoral arteries 24 hours later using an X-ray fluoroscope to confirm arterial occlusion. Thereafter, the animals were perfused with 100 mL of Ringer's lactate containing heparin sodium (1000 U) and isosorbide dinitrate (1 mg) and 100 mL of fixing solution (95% ethanol and 1% glacial acetic acid solution) and euthanized with an intraperitoneal injection of pentobarbital. When blood flow was observed until the end of experimental period (day 70), angiography was performed as described above, and the rabbits were euthanized.
Experimental Protocol 2
We prepared 25 rabbits for experimental protocol 2 as described in experimental protocol 1. Immediately after balloon injury, the rabbits were randomly divided into 3 groups: (1) 
Histopathology and Immunohistochemistry
Bilateral femoral arteries were dissected and fixed in 3.7% formaldehyde. The femoral arteries were then cut into long-axis segments to observe the whole thrombotic occlusion or short-axis (5 mm) segments. The segments were embedded in paraffin, and short-axis segments were cut every 5 µm for serial sections. A single observer who was blinded to the experimental protocol performed the morphometric analyses with hematoxylin and eosin staining. Serial femoral arterial sections were deparaffinized, and endogenous peroxidase was blocked by incubation with 0.3% H 2 O 2 in methanol for 5 minutes. For antigen retrieval, the sections were boiled for 20 minutes in citrate buffer (pH=6.0). After blocking with 3% skim milk, the sections were incubated overnight at 4°C with a primary antibody: platelet endothelial cell adhesion molecule 1 (PECAM-1; 1 μg/mL; catalog number SC-1506, Santa Cruz Biotechnology), antimacrophage antibody (RAM11; with recommended dilution 1:100; catalog number M0633, DAKO, Denmark), α-SMA (α-smooth muscle actin with recommended dilution 1:100; catalog number M0851, DAKO, Denmark), smooth muscle myosin heavy chain (SM-1, SM-2; with recommended dilution 1:100; catalog numbers 7600 and 7602, respectively, Yamasa Corp, Japan), and TF (10 μg/mL; catalog number 4513; American Diagnostica Inc). Normal mouse IgG (catalog number sc-2025, Santa Cruz Biotechnology) was used as a negative control. The sections were then incubated with biotin-conjugated secondary antibodies. Then, the sections were washed and treated with avidin peroxidase. The sections were developed using a DAB substrate kit (catalog number 045-22833, Wako Pure Chemical Industries, Osaka, Japan), and nuclei were counterstained with Mayer's hematoxylin. A single observer who was blinded to the experimental protocol performed the quantitative analysis. All images were captured by an Olympus microscope equipped with a digital camera (HC-2500) and were analyzed using Adobe Photoshop 6.0 (Adobe Systems, San Jose, CA) and ImageJ 1.45s Software (National Institutes of Health).
Coagulation Factor Xa Measurement in Peripheral Blood
Peripheral blood was obtained from rabbits when the femoral arteries were occluded or at day 70 if thrombotic occlusion did not occur by the end of experimental protocol 1. Coagulation factor Xa was assayed using a Rabbit Coagulation Factor Xa ELISA Kit (catalog number 040338, MyBiosource) according to the manufacturer's instructions.
Measurement of Serum Cholesterol Levels
Peripheral blood was obtained from rabbits on day 0 (serum A 
Measurement of Serum Oxysterol Levels
Serum lipids were extracted from peripheral blood collected on days 0, 14, 28, and when thrombotic occlusion was confirmed or day 70 of the treatment protocol using the Bligh and Dyer method. The samples were allowed to saponify at room temperature overnight in the dark. Unsaponified lipids were extracted 3× with n-hexane. Cholesterol was separated from the oxysterols using solid-phase extraction because it interferes with the measurement of oxysterols. Oxysterols were quantified via gas chromatography mass spectrometry using a GC/ MS QP2010 system (Shimadzu, Co, Kyoto, Japan) equipped with an SPB-1-fused silica capillary column of 60 m×0.25 mm and 0.25 μm phase thickness (Supelco Inc, Bellefonte, PA). Heat map was used with the aim of ordering the protein expression levels of the study end point according to the row obtained Z score (ie, z=[x−mean]/SD).
Measurement of Serum C-Reactive Protein Levels
Serum C-reactive protein levels at baseline (day 0) and the end of study protocol (the day thrombotic occlusion was confirmed or day 70 if thrombotic occlusion did not occur) were measured by latex agglutination turbidimetry (catalog numbers 341540 and 341571, NanopiaCRP, Sekisui Medical Co, Ltd, Tokyo, Japan) according to the manufacturer's instructions.
Evans Blue Permeability Assay
Re-endothelialization of rabbit femoral arteries was determined by the Evans blue permeability assay as previously described. 35 Endothelial regeneration of injured arteries was analyzed 30 minutes, 2 weeks, and 4 weeks after balloon injury by intravenous injection of Evans blue dye (50 mg/kg) 30 minutes before the vessels were harvested from the rabbits.
Cell Culture
Rat aortic SMCs (RASMCs) and human umbilical vein ECs (HUVECs) were used in this study. RASMCs (Cell Applications, Inc, San Diego) were cultured in DMEM (Sigma-Aldrich) containing 10% fetal bovine serum (Thermo Scientific, Waltham, MA), 1% penicillin (Invitrogen, Carlsbad, CA), and streptomycin (Invitrogen). HUVECs (Lonza) were maintained in endothelial basal medium-2 (Lonza) containing 10% fetal bovine serum, 1% penicillin, and streptomycin. RASMCs and HUVECs were maintained at 37°C in humidified air with 5% CO 2 , as previously described. 36 Nonadherent cells were removed, and the adherent cells were used between passages 3 and 6 for experiments.
Real-Time Polymerase Chain Reaction
RNA was extracted from RASMCs with ISOGEN (Nippon Gene, Tokyo, Japan), and cDNA was synthesized with a PrimeScript RT Reagent Kit (catalog number RR037A, Perfect Real Time, TAKARA BIO Inc, Shiga, Japan). Real-time polymerase chain reaction was performed with SYBR Premix DimerEraser (catalog number RR091A, Perfect Real Time, TAKARA BIO Inc) on a StepOnePlus real-time polymerase chain reaction system (Applied Biosystems, MA). The primer sequences of rat TF are 5′-CTTTCTCGGCTTCCTTCTCCTT-3′ and 5′-AGTTAAATTAAACGCTTTCCCTGGA-3′ (reverse and forward, respectively) (Sigma-Aldrich, Japan). The data were calculated using the ΔΔCt method and expressed in arbitrary units that were normalized to the GAPDH (Rn01775763_g1; Applied Biosystems) levels.
Western Blot Analysis
Protein was extracted from cultured RASMCs. The samples were homogenized in lysis buffer containing 10 mmol/L Tris-HCl, pH 7.4, 50 mmol/L NaCl, 5 mmol/L EDTA, 1% Triton X-100, 30 mmol/L sodium phosphate, 50 mmol/L NaF, 1% aprotinin, 0.5% pepstatin A, 2 mmol/L phenylsulfonyl fluoride, 5 mmol/L leupeptin, and phosphatase inhibitor cocktail (Pierce, Rockford, IL). The cell lysates (20 μg) were separated on 7.5% polyacrylamide gels and blotted onto polyvinylidene difluoride membranes (Millipore Co, Hercules, CA). Protein expression was analyzed using a monoclonal antibody against rat TF (ab151748, 0.212 μg/mL, Abcam) or GAPDH (Sigma). Immune complexes were visualized with horseradish peroxidase-conjugated secondary antibodies. Bound antibodies were detected by chemiluminescence using an ECL detection system (Amersham Biosciences) and quantified by densitometry.
Protein Array
The amounts of cytokines in rabbit model serum were measured using a protein array system (Bio-Plex) and analyzed with the accompanying system software (Bio-Plex Manager 2.0; all from Bio-Rad Laboratories, Inc). We chose a human cytokine assay kit (Bio-Plex Pro human cytokine GI 27-plex panel no. M500KCAF0Y; Bio-Rad Laboratories, Inc) because the anti-human antibodies in this kit have been previously reported to have cross-reactivity with rabbit antigens. 37, 38 All procedures were performed according to the manufacturer's instructions. Briefly, 50 μL of rabbit model serum (diluted 1:4) was added to the same volume of antibody-conjugated beads in a 96-well filter plate and incubated at room temperature for 1 hour. After a series of washes to remove the unbound proteins, 25 μL of the biotinylated detection antibody-lysate solution was sonicated on ice. After a series of washes, 50 μL of 1× streptavidin, R-phycoerythrin conjugate was added to each well. Then, a series of washes was performed again, the beads were resuspended, and the plate was read. Heat map was used with the aim of ordering the protein expression levels of the study end point, according to the row obtained Z score (ie, z=[x−mean]/SD).
Scratch Assay
HUVECs were plated in a 6-well tissue culture-treated plate in complete growth medium to achieve ≈80% confluency. The cells were allowed to adhere for 24 hours and then scraped with a P-200 micropipette tip. Detached cells were aspirated, and the complete growth medium was replaced. The HUVECs were then incubated at 37°C, and serial images were captured at designated time points at ×100 magnification. A standardized grid was placed over the images across the breadth of the denuded zone, and cells migrating into this zone were counted in a blinded fashion using ImageJ software.
Cell Proliferation Assay
HUVEC proliferation was analyzed using a Click-iT EdU Alexa Fluor 488 Imaging Kit (catalog number C10337, Thermo Fisher Scientific, MA). All procedures were performed according to the manufacturer's instructions. Briefly, after 24 hours of starvation with 0.1% fetal bovine serum, HUVECs were stimulated with cholesterol, 27HC, 7β-hydroxycholesterol (7βHC), 7α-hydroxycholesterol (7αHC), or 7KC (10 or 100 nmol/L) for 3 hours, and proliferating cells were detected with Alexa Fluor 488.
Measurement of Nitric Oxide
Nitric oxide (NO) release from HUVECs was analyzed using NO2/ NO3 Assay Kit-C II (Colorimetric; catalog number NK05, DOJINDO, Kumamoto, Japan). All procedures were performed according to the manufacturer's instructions. Briefly, after 24 hours starvation with 0.1% fetal bovine serum, HUVECs were stimulated with 10× diluted serum from rabbits for 24 hours. Then, NO 2 and NO 3 concentrations in culture supernatant were measured by Griess method.
Statistical Analysis
All data were reported as the mean±SEM. Differences were analyzed using Student t test for comparisons of 2 groups. For multiple comparisons among 3 groups or more, we selected Bonferroni post hoc test to compare each group with other groups. But when it was appropriate to compare each group only with the control group, we selected Dunnett. F test was performed before t test or ANOVA with parametric post hoc test, and there were no significant differences in the variance of each group. Occlusion-free survival curves were assessed by log-rank analysis. P<0.05 was considered statistically significant.
Results
Spontaneous Atherothrombotic Occlusions Frequently Occurred in Rabbit Femoral Arteries After Balloon Injury in Angiotensin II-Infused Group
We first developed a rabbit model of plaque erosion by adding angiotensin II infusion to a rabbit model of neointimal formation in preliminary experiment 1 ( Figure IIA in the online-only Data Supplement). 26, 27 Japanese white rabbits fed a high-cholesterol diet for 2 weeks were subjected to balloon injury in bilateral femoral arteries as shown in Figure IIB in the online-only Data Supplement. Angiotensin II was infused via an osmotic mini-pump (50 ng/kg per minute) for 4 weeks after balloon injury, and the animals were euthanized at week 8. At this time point, although no occlusions were found in any of the 8 arteries in the 4 animals in the vehicle group, 10 of the 16 arteries in the 8 animals in the angiotensin II-treated group were found to be occluded by fresh or organized thrombosis ( Figure IIIA and IIIB in the online-only Data Supplement). We analyzed serum factor Xa as a common downstream molecule of both intrinsic and extrinsic coagulation pathways. Serum factor Xa was equally elevated in the angiotensin II-treated group regardless if they developed occlusion or not ( Figure  IIIC in the online-only Data Supplement), suggesting that serum factor Xa was elevated by angiotensin II infusion, not as a consequence of thrombosis/platelet activation. Because oral treatment with a Xa inhibitor prevented thrombotic occlusion (data not shown), elevation of factor Xa is a precondition for thrombotic occlusion in this model.
Based on this preliminary experiment, we extended the angiotensin II infusion period to 8 weeks and performed echography 3× a week to detect thrombosis and the absence of blood flow in subsequent prospective experiments ( Figure 1A and 1B). Aspirin was administered for 2 weeks to prevent acute occlusion after balloon injury. When thrombotic occlusion was suspected, angiography was performed to confirm the arterial occlusion ( Figure 1C ). As shown in Figure 1D , arterial occlusion was observed in 1 of 5 animals in the vehicle group, whereas 6 of 6 femoral arteries in the angiotensin IItreated group were occluded during the experimental period ( Figure 1D ). Blood pressure and heart rate were comparable between the vehicle and angiotensin II-treated groups (67±5 versus 64±3 mm Hg, 162±10 versus 168±7 beats per minute). Echography showed no significant difference in the degree of stenosis between occluded and nonoccluded arteries (50±13% versus 49±19%; P=0.90). In angiotensin II-treated animals, arterial occlusion occurred between 2 and 7 weeks after injury, suggesting that injured arteries were exposed to the risk of thrombotic occlusion by delayed re-endothelialization. Serum factor Xa, which activates thrombin, was significantly elevated by angiotensin II (P=0.04; Figure 1E ).
Pathological Features of the Rabbit Model of Plaque Erosion
Immunohistochemical analysis of the injured arteries revealed several features of plaque erosion in this model. First, plaque rupture, that is, fibrous cap disruptions or intraplaque hemorrhage, was absent in both the vehicle and angiotensin II groups. Second, ≈90% of the luminal surface was covered with PECAM-1-positive ECs in the vehicle group, whereas there was no PECAM-1-positive endothelial layer at the site of thrombotic occlusion in injured arteries in the angiotensin II-treated group. Third, immature SMCs (SM1 39-41 at the neointima/thrombus interface were coimmunostained with TF in angiotensin II-treated animals. Fourth, few RAM11-positive macrophages observed at the neointima/thrombus interface in angiotensin II-treated animals (Figure 2A and 2B) . We confirmed and quantified the re-endothelialization of injured arteries using an Evans blue permeability assay. 35 Evans blue dye extravasation was observed in 60% of the luminal surface 30 minutes after balloon injury while extravasation was observed in only 18% of the luminal surface 2 weeks after balloon injury in the vehicle group. By contrast, Evans blue dye extravasation did not decrease in angiotensin II-treated animals, suggesting impaired reendothelialization ( Figure 2C ). Immunohistochemical analysis at 4 weeks after balloon injury revealed that 90% of the luminal circumferences were covered by ECs in the vehicle group while re-endothelialization was observed in ≈60% of the luminal circumferences in angiotensin II-treated animals ( Figure 2D ). These findings are consistent with the histopathologic features of plaque erosion observed in human coronary arteries, suggesting that the absence of an endothelial layer and TF-induced activation of the coagulation pathway cause thrombotic occlusion in plaque erosion.
Ezetimibe, But Not Rosuvastatin, Prevents Atherothrombotic Occlusion
In this rabbit model, we examined the efficacies of the clinically available lipid-lowering agents rosuvastatin and ezetimibe (experimental protocol 2, Figure IV in the online-only Data Supplement). We determined the doses of rosuvastatin and ezetimibe required to attain equivalent total cholesterol levels, which were confirmed in preliminary experiment 2 ( Figure V in the online-only Data Supplement). Thrombotic occlusion was significantly decreased by ezetimibe, but not by rosuvastatin, compared with the vehicle group ( Figure 3A ; P<0.05). Color Doppler echography and histopathologic analysis found no significant differences in the lumen area of balloon-injured femoral arteries among the 3 groups, in either occluded or nonoccluded arteries ( Figure 3B ). Histopathologic analyses also revealed that (1) treatment with ezetimibe decreased TF expression in the thickened intima compared with vehicle (P<0.0001) and rosuvastatin (P<0.05) treatment, (2) the intima/media ratio was comparable among the 3 groups while the medial and intimal thicknesses were significantly decreased only in rosuvastatin-treated animals as previously reported, 42 and (3) re-endothelialization determined by PECAM-1 staining was significantly increased in the ezetimibe group compared with the vehicle group ( Figure 3B and 3C) . We quantified the reendothelialization of injured arteries in the ezetimibe group using an Evans blue permeability assay. The extravasation of Evans blue dye was significantly decreased in the ezetimibe group compared with the vehicle group 4 weeks after balloon injury (12% and 47%, respectively, Figure 3D ). Body weights at the end of experimental period were comparable among the 3 groups. Weight gain during this period was also similar ( Figure  VIA in the online-only Data Supplement). Hemodynamic parameters, including heart rate and systolic/diastolic/mean blood pressure, were also comparable among the 3 groups ( Figure VIB and VIC in the online-only Data Supplement).
Ezetimibe Reduces Both Enzymatically and Nonenzymatically Generated Oxysterols in Rabbits
To address the molecular mechanisms, we examined serum factors that may impair proliferation/migration in ECs or induce TF expression in VSMCs using gas chromatography mass spectrometry and the Bio-Plex multiplex immunoassay system. As shown in Table 1 , serum lipid and oxysterol levels gradually increased in the vehicle group during the study period. Both rosuvastatin and ezetimibe monotherapy significantly decreased total cholesterol levels to comparable degrees at week 4 and at the end of study ( Figure 4A ; Tables 1  and 2 ). There was no significant difference in serum triglyceride and high-density lipoprotein cholesterol levels between the rosuvastatin and ezetimibe groups (Table 1) .
Several oxysterols, including 7KC and 27HC, which are reported to be atherogenic, 20, 43, 44 were increased in angiotensin II-infused vehicle group compared with no angiotensin IIinfused group (Figure VII in the online-only Data Supplement) Figure 3 . Ezetimibe (Eze) decreases thrombotic occlusion of balloon-injured femoral arteries in hyperlipidemic rabbits. A, Occlusion-free survival curve. A log-rank (Mantel-Cox) test was used for data analysis. *P<0.05. B, Morphometric analyses of injured femoral arteries. n=12, 7, and 9. C, Immunostaining of TF (tissue factor) and platelet endothelial cell adhesion molecule 1 (PECAM-1). Quantitative analyses of TF-positive areas in the neointima and re-endothelialization. n=12, 7, and 9. Scale bar indicates 200 μm. D, Quantitative results of an Evans blue permeability assay. n=3 each. One-way ANOVA followed by Bonferroni multiple comparison tests was used for data analyses in B and C, and unpaired t test was used in D. *P<0.05; **P<0.01; ****P<0.0001. ns indicates not significant; Ros, rosuvastatin group; and Ve, vehicle group. and decreased only in the ezetimibe group compared with the vehicle or rosuvastatin group ( Figure 4B ; Table 2 ). On-treatment oxysterol levels were significantly lower in occlusion (−) animals compared with occlusion (+) animals regardless of whether they were treated with vehicle, rosuvastatin, or ezetimibe while total cholesterol levels were equivalent between occlusion (−) animals and occlusion (+) animals. The fraction of total oxysterol in total cholesterol was lower in the ezetimibe group and higher in the rosuvastatin group compared with the vehicle group (Figure VIII in the onlineonly Data Supplement). However, representative inflammatory cytokines/chemokines, including interleukin-1β, interleukin-6, and tumor necrosis factor-α, were significantly elevated in the serum of the vehicle group compared with control animals without angiotensin II infusion, and these increases were ameliorated by both rosuvastatin and ezetimibe. There was no significant difference in these protein levels between the rosuvastatin and ezetimibe groups ( Figure 4C ). The serum C-reactive protein levels of rabbits fed high-cholesterol diet and angiotensin II infusion were significantly elevated compared with rabbits fed normal chow diet with no angiotensin II infusion, which was significantly decreased by both rosuvastatin and ezetimibe ( Figure IX in the online-only Data Supplement).
Induction of EC Proliferation Was Attenuated in Serum From EzetimibeTreated Rabbits as Compared With Serum From Vehicle-Treated Rabbits
The association between oxysterols and thrombosis in the animals prompted us to examine the effects of rabbit serum or oxysterols on cultured ECs and SMCs. We first performed a scratch assay in HUVECs to examine the effects of rabbit model serum. We treated HUVECs with 10 ng/mL concentration of vascular endothelial growth factor plus 10% rabbit model serum (serum A, normal chow group; serum B, high-cholesterol diet group; serum C-Ve, vehicle group; serum C-Ros, rosuvastatin group; and serum C-Eze, ezetimibe group). Vascular endothelial growth factor significantly induced HUVEC migration while sera B, C-Ve, and C-Ros inhibited vascular endothelial growth factor-induced proliferation of HUVECs. Interestingly, serum C-Eze improved the migration of HUVECs compared with serum C-Ve (P<0.01) and serum C-Ros (P<0.05; Figure 5A ; n=3-6, each).
We then examined the effects of oxysterols on cultured ECs. Of the 10 oxysterols detected in the sera of animals, we examined 4 that were relatively abundant in the vehicle group and significantly decreased in the ezetimibe group: 7KC, 7αHC, 7βHC, and 27HC. In a HUVEC scratch assay, 7KC reduced migration in concentration-dependent manner while cholesterol showed no significant effects at the concentrations examined (0-100 μmol/L; n=3 in each group; Figure 5B ). In a 5-ethynyl-2′-deoxyuridine cell proliferation assay, 7KC significantly decreased cell counts and the number of 5-ethynyl-2′-deoxyuridine-positive proliferating cells in a concentration-dependent manner ( Figure 5C ). Another oxysterol, 7αHC (100 μmol/L), also decreased the number of 5-ethynyl-2′-deoxyuridine-positive proliferating cells, but this effect required a concentration >30-fold higher than that found in the sera of animals.
Finally, we examined the release of NO from the cultured ECs by the stimulation of 10% sera from rabbit models. NO release was induced by serum A, but serum C-Ve significantly decreased NO release. This reduction, however, was attenuated in serum C-Eze but not serum C-Ros. Although it is difficult to examine the change of endothelial function in vivo, this result may indirectly suggest the improvement of endothelial function in lower existence of serum oxysterols (Figure X in the online-only Data Supplement). This result indicates a possibility that improvement of endothelial function by ezetimibe promoted antithrombogenicity by inhibiting platelet activation. 45, 46 
TF Expression in VSMCs Was Attenuated in Serum From Ezetimibe-Treated Rabbits as Compared With Serum From Vehicle-Treated Rabbits
Histochemical analyses revealed that angiotensin II induced TF expression in the neointima that comprises immature VSMCs ( Figure 2B ) and that treatment with ezetimibe decreased TF expression compared with vehicle or rosuvastatin ( Figure 3C ). Therefore, we also examined the effects of animal model serum on VSMCs (serum A, normal chow group; B, high-cholesterol diet group; C-Ve, vehicle group; C-Ros, rosuvastatin group; and C-Eze, ezetimibe group).
As shown in Figure 6A , serum B increased the TF protein level compared with serum A while its effect on the mRNA expression was not significant (6.4-fold increase in mRNA), and serum C-Ve further increased TF expression compared with serum B. Serum C-Ve increased the TF mRNA and protein levels by ≈30-fold and 8-fold, respectively, compared with serum A. Serum C-Eze significantly attenuated TF expression at both the mRNA (P<0.001) and protein (P<0.01) levels compared with serum C-Ve while serum C-Ros did not attenuate TF expression at either the mRNA or protein level.
To examine the effect of oxysterols on TF expression in RASMCs, we incubated RASMCs with cholesterol (1-100 μmol/L) or 4 oxysterols (0.1-10 μmol/L): 7KC, 27HC, 7αHC, or 7βHC. Although cholesterol, 7αHC, and 7βHC did not induce TF at the maximum concentration used, 7KC and 27HC increased TF mRNA at 0.1and 1 μmol/L, respectively ( Figure 6B ). Taken together, these data indicate that 7KC and 27HC contributed to TF expression in VSMCs at the injury site and to thrombus formation, which were attenuated by treatment with ezetimibe.
To address the molecular mechanisms of TF induction by oxysterols, we examined 2 molecular pathways: toll-like receptor (TLR) 4 signaling and redox signaling. It has been reported that 7KC-induced signals are mostly mediated by TLR4. 47 Hence, we examined whether the induction of TF expression by 7KC or 27HC (10 μmol/L) was suppressed by TAK-242 (resatorvid), a small molecule and specific inhibitor of TLR4. TAK-242 (1 μmol/L) did not suppress 7KC-or 27HC-induced TF expression in RASMCs even after 60 minutes of pre-treatment (the IC 50 value was reported to be 1.1-11 nmol/L in RAW264. . Ezetimibe (Eze) significantly reduces serum oxysterol levels compared with rosuvastatin. A, Serum cholesterol levels. n=11, 5, and 7. *P<0.05; **P<0.01. B, Serum levels of total oxysterol, 7-ketocholesterol (7KC), and 27-hydroxycholesterol (27HC). n=7, 5, and 7. *P<0.05; **P<0.01; ***P<0.001. C, Protein array of 23 cytokines and chemokines. n=6, 7, 5, and 7. **P<0.01; ****P<0.0001. For data analyses, 1-way ANOVA followed by Bonferroni multiple comparison tests was used for data analyses in A to C. Ang II indicates angiotensin II; Ctrl, control; IL, interleukin; ns, not significant; Ros, rosvastatin; TNF, tumor necrosis factor; ve, vehicle; and VEGF, vascular endothelial growth factor.
vehicle group (Figure XIB in the online-only Data Supplement). Next, we examined the effect of N-acetyl-l-cysteine (NAC), a reactive oxygen species scavenger, to study the involvement of redox signaling. TF expression was significantly attenuated after a 60-minute pre-treatment with NAC (5 mmol/L) in both 7KC-and 27HC-treated RASMCs ( Figure 6C) . Similarly, pretreatment with NAC attenuated TF induction by serum C-Ve or serum C-Ros in RASMCs. Importantly, NAC failed to significantly attenuate TF expression induced by serum C-Eze ( Figure 6D ). These results suggest that 7KC and 27HC induce TF expression in VSMCs mainly through redox signaling and that the difference between rosuvastatin and ezetimibe is because of the reduction in oxysterols only by ezetimibe.
Discussion
This study presents several novel findings: (1) the development of a new rabbit model of plaque erosion that mimics spontaneous atherothrombosis in patients with ACS; (2) the decrease of atherothrombosis by lipid-lowering therapy with ezetimibe, which was associated with the reduction in oxysterols; and (3) the causative roles of oxysterols in the migration and proliferation of ECs and TF expression in VSMCs by redox-mediated mechanisms.
New Animal Model of Spontaneous Atherothrombotic Occlusion Associated With Plaque Erosion
In this study, we demonstrated for the first time that spontaneous atherothrombotic occlusion without plaque rupture frequently occurred in rabbit femoral arteries after high-cholesterol diet feeding, balloon injury, and angiotensin II infusion ( Figures 1D and 3A) , which were associated with serum factor Xa elevation Figure IIC in the online-only Data Supplement; Figure 1E ). Rabbits are suitable for studying arterial thrombosis because their coagulation and fibrinolysis systems are similar to those of humans. 49 Immunohistochemical analyses revealed that our new model had key pathological features of plaque erosion seen in human coronary arteries as follows 3, 50 ; (1) lack of a PECAM-1-positive endothelial layer at the site of thrombotic occlusion, and (2) poor macrophage infiltration in SMC-rich intima. However, they had no pathological features of plaque rupture observed in human coronary arteries as below 3, 4 ; (1) the existence of necrotic core, lipid-rich pool and disruption of fibrous caps, and (2) abundant macrophage infiltration (Table II in 
Previous Studies Have Reported Animal Models of Thrombus Formation Induced by Acute Chemical or Mechanical Injuries
Yamashita et al 26 have previously reported that repeated balloon injuries of rabbit femoral artery induce acute TF-mediated Each oxysterol component is shown as μg/dL. Data are expressed as mean±SEM and compared using 1-way ANOVA followed by Bonferroni multiple comparison test. β-EPOX indicates cholesterol β-epoxide; E, enzymatically generated; E/N, both enzymatically and nonenzymatically generated; Eze, ezetimibe; N, nonenzymatically generated; Ros, rosuvastatin; TRIOL, cholestane-3β-5α-6β triol; and Ve, vehicle. thrombosis. They also reported that flow limitation by a vascular occluder in rabbit femoral arteries, underwent balloon injury 3 weeks before, induce acute occlusive thrombosis in 3 of 5 vessels, 27 suggesting that oscillatory shear stress induced by flow-limiting stenosis induced endothelial detachment and subsequent thrombus formation. In these experiments, For data analyses, 1-way ANOVA followed by Bonferroni multiple comparison tests was used in A, and Dunnett was used in B and C. Serum A indicates serum collected from normal chow group; B, from high cholesterol diet group; C-Ve, from vehicle group; C-Ros, from rosuvastatin group; C-Eze, from ezetimibe group. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001. HC indicates hydroxycholesterol; ns, not significant; and VEGF, vascular endothelial growth factor. thrombus formations were observed within 3 hours after induction (ie, balloon injury or flow limitation). Durand et al 32 demonstrated that staurosporine induced acute erosive injury because of EC apoptosis and subsequent thrombosis in the atherosclerotic-like lesion induced in femoral arteries of rabbits by the combination of air desiccation and high-cholesterol diet. In this experiment, thrombosis occurred in 7 of 12 animals, but the rate of occlusive thrombosis was just 25% (3 of 7 animals with thrombosis), and 4 of 7 arteries experienced nonocclusive thromboses. 32 In our study, by contrast, chronic continuous angiotensin II infusion via an osmotic pump induced thrombotic occlusion with high frequency (15 of 17 animals) 2 to 8 weeks after initiation (Figures 1D and 3A ; Table III in the online-only Data Supplement). These rather spontaneous and high-frequent occurrences of atherothrombotic occlusions allowed us to investigate the pathological process and the therapeutic effects of medical interventions on plaque erosion.
Ezetimibe Decreases Spontaneous Atherothrombotic Occlusions by Reducing Circulating Oxysterols
In this study, we found that ezetimibe, but not rosuvastatin, prevented thrombotic occlusion in our new animal model of plaque erosion. Immunohistochemical analysis revealed that ezetimibe improved re-endothelialization and suppressed TF expression in the intima ( Figure 3C ). Serum cholesterol and inflammatory cytokine/chemokine levels were comparable Figure 6 . A reactive oxygen species scavenger, N-acetyl-l-cysteine (NAC) inhibits TF (tissue factor) mRNA induction by serum from balloon-injured rabbits. A, Expression of TF mRNA (left) and protein (right) in cultured rat aortic smooth muscle cells (RASMCs) treated with 10× diluted sera from balloon-injured rabbits. n=3 to 8 (left) and 3 to 4 (right). B, Expression of TF mRNA in cultured RASMCs treated with oxysterols. n=4 each. C, Effect of pre-treatment with 5 mmol/L NAC on TF mRNA expression in RASMCs treated with 7-ketocholesterol (7KC; 10 μmol/L) or 27-hydroxycholesterol (27HC; 10 μmol/L). n=6 to 9 each. D, Effect of pre-treatment with NAC on the mRNA expression of TF in RASMCs incubated with serum from balloon-injured rabbits treated with the indicated agents in the graph. n=3 to 4 each. For data analyses, 1-way ANOVA followed by Bonferroni multiple comparison tests was used in A to C. Serum A indicates serum collected from normal chow group; B, from high-cholesterol diet group; C-Ve, from vehicle group; C-Ros, from rosuvastatin group; C-Eze, from ezetimibe group. **P<0.01; ***P<0.001; ****P<0.0001. ns indicates not significant; and RT-PCR, reverse transcription polymerase chain reaction.
between treatment groups; however, both enzymatically and nonenzymatically generated oxysterols were significantly lowered by ezetimibe monotherapy, as shown in Figure 4B and Table 2 . These findings confirmed the results of our previous clinical study, 24 which indicated that the combination of ezetimibe and statins significantly reduced both enzymatically and nonenzymatically generated oxysterols compared with statins alone. A recent study by Lin et al 52 showed that ezetimibe accelerated the removal of endogenous cholesterol and therefore turnover of the cholesterol pool in humans, which may be responsible for the reduction of enzymatically generated oxysterols and nonenzymatically generated oxysterols by ezetimibe. The reduction in oxysterols induced by ezetimibe compared with rosuvastatin was significant even when on-treatment cholesterol levels were equivalent in this study, underpinning our findings in the subgroup analysis in our clinical study. 24 In this study, we revealed in vivo oxidation with angiotensin II elevates both enzymatically and nonenzymatically generated oxysterols in high-cholesterol diet-fed rabbits ( Figure VII in the online-only Data Supplement). Angiotensin II infusion that might induce oxidative stress in the media tunica, 53 might induce nonenzymatic oxidation of cholesterol to form, for example, 7KC or 7βHC although further investigations are needed to examine the mechanisms by which angiotensin II induces enzymatic formation of, for example, 27HC. As shown in Table 2 , ezetimibe inhibited 7KC, one of the nonenzymatically generated oxysterols at day 28 and finally reduced both enzymatically and nonenzymatically generated oxysterols. Although further investigations are needed to define whether ezetimibe influenced the decrease of oxysterols that was generated by in vivo oxidation with angiotensin II, it was appropriate to consider that ezetimibe affected the residual 2 main source of circulating oxysterols other than angiotensin II-induced in vivo oxidation, which are exogenously absorbed cholesterol and enzymatically generated oxysterols because ezetimibe does not participate in the inhibition of cholesterol synthesis in the liver. So we considered both the absorption of nonenzymatically generated oxysterols and the reabsorption of enzymatically generated oxysterols in enterohepatic circulation at small intestine finally lead ≈60% reduction of serum oxysterols in ezetimibe group compared with vehicle ( Table 2) .
Total oxysterol levels were significantly lower in nonoccluded animals than in occluded animals, regardless of the lipid-lowering therapies, while total cholesterol levels were equivalent between nonoccluded animals and occluded animals ( Figure VI in the online-only Data Supplement). These associations suggest that oxysterols contributed to the formation of thrombotic occlusions by promoting poor re-endothelialization of denuded ECs and increased TF expression in intimal SMCs in addition to the formation of atherosclerotic lesion. We identified 4 oxysterols, 7KC, 7αHC, 7βHC, and 27HC, that were relatively abundant and significantly reduced by treatment with ezetimibe both in this study and our previous clinical study and examined their effects on cultured ECs and VSMCs. 24 One of the enzymatically generated oxysterols, 27HC, has been reported to inhibit estradiol-induced EC migration and re-endothelialization in mice in an estrogen receptor-α-dependent manner. 43 Representative nonenzymatically generated oxysterols oxidized at carbon 7, especially 7KC and 7βHC, are the major oxysterols found in oxidized lowdensity lipoprotein and are toxic to ECs. 54 In our study, in vitro HUVEC proliferation and migration assays revealed that only 7KC had detrimental effects on the process of re-endothelialization when the concentration of each oxysterol was adjusted to that found in model serum. Although further investigation is needed to determine why 27HC did not suppress the proliferation and migration of HUVECs in our study, we hypothesized that it was because the absence of estradiol induction and poor estrogen receptor-α expression in HUVECs. 55 The effect of rabbit serum on migration suggests that the reduction of oxysterols, including 7KC, by ezetimibe accelerated re-endothelialization compared with statin treatment.
Mechanism of Oxysterol-Induced TF Expression in VSMCs
In the present study, the serum from vehicle or rosuvastatintreated rabbits induced TF expression at both the mRNA and protein levels. The serum from ezetimibe-treated rabbits, in which the concentrations of oxysterols were reduced, had smaller effects on TF induction. As shown in Figure 6 , 7KC and 27HC at concentrations found in the serum of animals induced TF mRNA expression in in vitro cultured VSMCs, supporting the causal role of oxysterols in TF induction in this model. Huang et al 47 reported that 7KC induces TF expression through TLR4. However, a specific TLR4 inhibitor, TAK-242, failed to block 7KC-, 27HC-, or serum-induced TF expression, excluding the role of TLR4. In this study, the reactive oxygen species scavenger NAC significantly attenuated TF expression in both 7KC-and 27HC-treated RASMCs. In addition, pre-treatment with NAC attenuated TF induction by serum from the vehicle or rosuvastatin groups, whereas it did not affect TF expression induced by serum from ezetimibetreated rabbits. The oxysterol 7KC is known to possess oxidizing capacity, which may activate redox-sensitive kinases (ie, the Jun/Fos, NF-κB [nuclear factor-κB], NFAT [nuclear factor of activated T cells], or Egr families) that regulate TF expression in VSMCs. 56 
Conclusions
In this study, we established an animal model of plaque erosion, which showed the efficacy of ezetimibe, but not rosuvastatin, in inhibiting thrombotic occlusion because of plaque erosion. Serum oxysterols, which were lowered by ezetimibe, may play a causative role in the development of thrombotic occlusion in this plaque erosion model by inhibiting re-endothelialization and inducing TF in SMCs through redox signaling. Because of its oxysterol-lowering effect, ezetimibe could be a clinically feasible therapeutic strategy to prevent acute thrombotic complications of plaque erosion.
As a clinical perspective, intensive lipid-lowering therapy by statins decreased cardiovascular events, but the reduction of coronary events is not sufficient and there remain residual risks. Here, we have demonstrated that ezetimibe decreases thrombotic occlusion after endothelial denudation accompanied with the reduction of circulating oxysterols. These results indicate a possibility of ezetimibe added on statin as an additive strategy to treat residual risks, especially associated with plaque erosion, although further studies, including clinical trials, are warranted to clarify the patient characteristics that will accept the benefit of ezetimibe added on statin.
